We are Sorry, This Page doesn't Exist
Genprex in-licenses gene therapy technologies for lung cancer treatment
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
OSU, Children’s start to see fruits of research labor
At long last, successes are piling up. The two Columbus institutions have generated not only revenue, but IPOs, several acquisitions, job-creating startups and an FDA-approved gene therapy that has normally non-effusive scientists using the term cure......»»
Uniqure"s Hemophilia B Gene Therapy Unlikely To Be Cause Of Liver Cancer Reported In One Patient
Uniqure NV (NASDAQ: QURE) has read more.....»»
The Daily Biotech Pulse: Novartis Funding For Gene Therapy Research, Priority Review For Amgen Cancer Drug, Pfizer-BioNTech Vaccine Supply Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 16) read more.....»»
Bluebird Bio Temporarily Suspends Sickle Cell Gene Therapy Studies Following Incidences of Blood Cancer
Shares of bluebird bio Inc (NASDAQ: BLUE) were sinking Tuesday morning following an adverse clinical pipeline development. read more.....»»
Biotech company Forty Seven surges 30% after hours on report of Gilead interest
Shares of cancer-therapy company Forty Seven Inc. shot up more than 30% in after-hours trading Thursday after a report that Gilead Sciences Inc. has made a takeover offer. Bloomber.....»»
Penny Stock Rips 260% Higher On Fast Track Designation For Experimental Lung Cancer Gene Therapy
Shares of thinly-traded gene therapy company Genprex Inc (NASDAQ: GNPX) are soaring on more than 50 times their average volume Tuesday. 0 read more.....»»
In deal with Gilead, stealthy East Bay startup turns cell therapy against autoimmune diseases
Cell therapy's initial applications have been in cancer. This deal could rev up its use against a wide range of diseases where the immune system goes wild and attacks the body......»»
Seattle Genetics" stock rises on approval of bladder cancer drug
The Food and Drug Administration on Wednesday approved Padcev as a treatment for metastatic urothelial cancer. The therapy is jointly being developed by Astellas Pharma Inc.....»»
Novartis"s $90 million Swiss factory to help solve cell therapy bottleneck
Swiss drugmaker Novartis's new $90 million cell and gene therapy factory in northern Switzerland is on track to begin commercial production of treatments, including Kymriah for cancer and Zolgensma for spinal muscular atrophy, in 2020......»»
Blackstone to invest $400 million in gene therapy venture with Ferring
Blackstone Group Inc said on Monday it will invest $400 million in a joint venture with Swiss drug company Ferring that is working on an experimental gene therapy for bladder cancer, the private equity giant's largest ever bet on drug development......»»
FTC staff recommends approval of Roche deal for Spark: report
The Federal Trade Commission staff reviewing Roche's plan to buy U.S.-based gene therapy specialist Spark Therapeutics for $4.3 billion recommended that the deal be approved without requiring any asset sales, the Capitol Forum reported on Thursday......»»
Krystal Clear: KB-103 Sprints To Become The First Approved Topical Gene Therapy For Skin Disease
Krystal Clear: KB-103 Sprints To Become The First Approved Topical Gene Therapy For Skin Disease.....»»
Durham drugmaker pushes forward with its latest clinical cancer treatment
Riding on the momentum of its recent initial public offering, a Triangle gene therapy company is launching its second potential cancer treatment into clinical trials......»»
FDA Investigates Data Manipulation Issue With Newly Approved Novartis Drug Zolgensma
Novartis AG (NYSE: NVS)'s Zolgensma, the first gene therapy approved for pediatric patients with spinal muscular dystrophy Type 1, has caught the FDA's attention due to a disclo read more.....»»
FDA: Novartis Hid Data Manipulation While Seeking Approval of $2.1 Million Drug
A Novartis AG unit that developed a breakthrough gene therapy knew about potential manipulation of animal testing data but failed to disclose it to regulators before the treatment was approved, the U.S. Food and Drug Administration said......»»
Gene therapy maker submitted manipulated data before drug was approved, FDA says
The maker of a newly approved $2 million gene therapy was aware that some of the testing data in its application to the Food and Drug Administration was manipulated, the agency said......»»
Shares of cancer-therapy companies skyrocket after Pfizer acquisition news
Shares of gene-therapy companies shot up on Monday after Pfizer Inc. announced it would acquire cancer drug maker Array BioPharma Inc. in a deal worth up to $11.4 billion......»»
Novartis gets FDA nod for advanced breast-cancer treatment
Novartis AG said late Friday the U.S. Food and Drug Administration has approved one of its treatments for a type of advanced breast cancer afflicting patients carrying a gene.....»»